A Study to Demonstrate the Effect of REGN5713-5715 on Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Birch Pollen Allergy
Completed · Phase 3 · NCT06602739
Conditions: Allergic Conjunctivitis
At a glance
- Research payments reported, 2025
- $1.0M
- U.S. investigators named
- 1
- Sites paid
- 2
- Planned or actual enrollment
- 54
About the trial
- Sponsor
- Regeneron Pharmaceuticals
- Tested
- REGN5713 (drug), REGN5715 (drug), Placebo (drug)
- Dates
- Started 2024-11-19; completion 2025-08-02
- Results posted
- Not yet
This study is researching 2 experimental drugs, REGN5713 and REGN5715, which are called REGN5713-5715 when mixed together (called "study drug") to reduce eye allergy signs and symptoms due to birch tree pollen allergy. The aim of the study is to see how safe and effective the study drug is at lowering allergic eye signs and symptoms compared with placebo. A placebo looks like a treatment but does not contain any real medicine. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the d…
From ClinicalTrials.gov, last updated 2026-04-21. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Regeneron Pharmaceuticals, Inc. reported $1.0M in research payments for this study in 2025 (1,017 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Andover Eye Associates Inc $667,746
- Aapri Clinical Research Institute $366,470
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.